U.S. Markets open in 3 hrs 30 mins

Santhera Pharmaceuticals Holding AG (SANN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
67.60+0.45 (+0.67%)
As of 11:12AM CEST. Market open.
Full screen
Previous Close67.15
Open67.55
Bid67.30 x 0
Ask67.60 x 0
Day's Range67.05 - 67.90
52 Week Range37.05 - 82.00
Volume3,235
Avg. Volume42,514
Market Cap424.34M
Beta1.31
PE Ratio (TTM)-11.96
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TheStreet.com2 years ago

    Santhera Drug Wins European Approval for Rare Blindness Disease

    The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.

  • TheStreet.com2 years ago

    Santhera Drug Win European Approval for Rare Blindness Disease

    The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients (mostly males) in Europe.

  • Reuters2 years ago

    Europe gives green light to new Novartis, Alexion drugs

    New drugs from Novartis and Alexion won a green light from European regulators on Friday, delivering a boost to both drugmakers and offering new treatment options for cancer and rare diseases. Experts from the European Medicines Agency (EMA) said they had recommended approval of Novartis's Farydak for multiple myeloma, an aggressive blood cancer, and Odomzo for basal cell carcinoma, a type of skin cancer.